170 related articles for article (PubMed ID: 17661178)
1. Bone density in women with prolactinoma treated with dopamine agonists.
Naliato EC; Violante AH; Caldas D; Farias ML; Bussade I; Lamounier Filho A; Loureiro CR; Fontes R; Schrank Y; Loures T; Colao A
Pituitary; 2008; 11(1):21-8. PubMed ID: 17661178
[TBL] [Abstract][Full Text] [Related]
2. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
3. Body fat in nonobese women with prolactinoma treated with dopamine agonists.
Naliato EC; Violante AH; Caldas D; Lamounier Filho A; Loureiro CR; Fontes R; Schrank Y; Souza RG; Costa PL; Colao A
Clin Endocrinol (Oxf); 2007 Dec; 67(6):845-52. PubMed ID: 17645576
[TBL] [Abstract][Full Text] [Related]
4. Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.
Camozzi V; Lumachi F; Mantero F; Piccolo M; Luisetto G
Osteoporos Int; 2003 Jul; 14(7):602-8. PubMed ID: 12730752
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in women with microprolactinoma treated with dopamine agonists.
Cesar de Oliveira Naliato E; Dutra Violante AH; Caldas D; Lamounier Filho A; Rezende Loureiro C; Fontes R; Schrank Y; Gomes de Souza R; Vaisman M; Guerra E; Sebastian A; Colao A
Pituitary; 2008; 11(3):247-54. PubMed ID: 18270842
[TBL] [Abstract][Full Text] [Related]
6. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
7. Body fat in men with prolactinoma.
Naliato EC; Violante AH; Gaccione M; Caldas D; Lamounier Filho A; Loureiro CR; Fontes R; Schrank Y; Costa FS; Colao A
J Endocrinol Invest; 2008 Nov; 31(11):985-90. PubMed ID: 19169054
[TBL] [Abstract][Full Text] [Related]
8. The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins.
Bolanowski M; Zadrozna-Sliwka B; Jawiarczyk A; Syrycka J
Gynecol Endocrinol; 2010 Aug; 26(8):623-7. PubMed ID: 20218822
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of osteopenia in men with prolactinoma.
Naliato EC; Farias ML; Braucks GR; Costa FS; Zylberberg D; Violante AH
J Endocrinol Invest; 2005 Jan; 28(1):12-7. PubMed ID: 15816365
[TBL] [Abstract][Full Text] [Related]
10. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
[TBL] [Abstract][Full Text] [Related]
11. Compromised bone density 11.4 years after diagnosis of anorexia nervosa.
Brooks ER; Ogden BW; Cavalier DS
J Womens Health; 1998 Jun; 7(5):567-74. PubMed ID: 9650157
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
Zadrozna-Sliwka B; Bolanowski M; Kałuzny M; Syrycka J
Endokrynol Pol; 2007; 58(2):116-22. PubMed ID: 17578827
[TBL] [Abstract][Full Text] [Related]
13. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
14. [Decreased bone mineral density in pre-menopause women with prolactinoma].
Bussade I; Naliato EC; Mendonça LM; Violante AH; Farias ML
Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1522-7. PubMed ID: 18209896
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise.
Seeman E; Szmukler GI; Formica C; Tsalamandris C; Mestrovic R
J Bone Miner Res; 1992 Dec; 7(12):1467-74. PubMed ID: 1481732
[TBL] [Abstract][Full Text] [Related]
16. Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.
Takeno A; Yamamoto M; Okazaki K; Yamaguchi T; Sugimoto T
Am J Case Rep; 2016 Mar; 17():160-4. PubMed ID: 26971354
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas, dopamine agonists and headache: two case reports.
Levy MJ; Matharu MS; Goadsby PJ
Eur J Neurol; 2003 Mar; 10(2):169-73. PubMed ID: 12603293
[TBL] [Abstract][Full Text] [Related]
18. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea.
Grinspoon S; Miller K; Coyle C; Krempin J; Armstrong C; Pitts S; Herzog D; Klibanski A
J Clin Endocrinol Metab; 1999 Jun; 84(6):2049-55. PubMed ID: 10372709
[TBL] [Abstract][Full Text] [Related]
19. Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology.
Vaneckova M; Seidl Z; Hana V; Jarkovska Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):841-5. PubMed ID: 18063932
[TBL] [Abstract][Full Text] [Related]
20. Giant prolactinomas in women.
Delgrange E; Raverot G; Bex M; Burman P; Decoudier B; Devuyst F; Feldt-Rasmussen U; Andersen M; Maiter D
Eur J Endocrinol; 2014 Jan; 170(1):31-8. PubMed ID: 24088550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
